HMB and Liraglutide Confer Complementary Protection Against Lipotoxic and Atrophic Alterations in High-Glucose Plus Free Fatty Acid-Treated C2C12 Myotubes
Nutrients · 09.06.2026 · 18 (12) · 1865
DOI: 10.3390/nu18121865 ↗Kurz gefasst
Fachartikel in der Zeitschrift Nutrients, online erschienen am 09.06.2026. Verfasst von Li-Yuan Chen und 9 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Medicine, Chung Shan Medical University, Taichung 402, Taiwan. Hauptthemen laut MEDLINE: Liraglutide, Muscle Fibers, Skeletal, Glucose, Fatty Acids, Nonesterified. Die Arbeit nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Chung Shan Medical University Hospital, National Science and Technology Council, National Chung Hsing University and Chung Shan Medical University.
Abstract (Originalsprache)
Background/Objectives: Type 2 diabetes (T2D)-associated sarcopenia is characterized by impaired insulin signaling, lipotoxicity, oxidative stress, and progressive muscle loss. Although liraglutide improves glucose control and reduces lipid burden, its ability to preserve muscle integrity under diabetic lipotoxic conditions remains limited. This study investigated whether β-hydroxy-β-methylbutyrate (HMB) could enhance liraglutide-mediated protection against high-glucose plus free fatty acid (HG+FFA)-induced injury in skeletal muscle cells.
Methods
Differentiated C2C12 myotubes were exposed to HG+FFA to establish a sublethal lipotoxic model and treated with liraglutide, HMB, or their combination. Cell viability, lipid accumulation, myotube morphology, insulin signaling, glucose uptake, mitochondrial function, reactive oxygen species (ROS), antioxidant gene expression, and atrophy-related signaling were assessed.
Results
HG+FFA induced marked lipid droplet accumulation, impaired insulin signaling, reduced glucose uptake, disrupted mitochondrial membrane potential, increased ROS production, suppressed antioxidant gene expression, and promoted an atrophic phenotype characterized by increased atrogin-1 and MuRF1 and reduced myogenic markers. Liraglutide alone reduced large lipid droplets and partially improved insulin signaling but showed limited efficacy in preserving the myotube phenotype. HMB alone exerted modest effects on lipid accumulation but preserved myotube area. Notably, combined HMB and liraglutide treatment more effectively reduced lipid burden, restored insulin signaling and glucose uptake, attenuated mitochondrial dysfunction and oxidative stress, restored antioxidant gene expression, and preserved MyHC-positive area and myotube diameter while suppressing atrogin-1/MuRF1 activation. These protective effects were largely attenuated by rapamycin, indicating at least partial dependence on mTOR-associated signaling.
Conclusions
Overall, HMB and liraglutide exert complementary protective effects against diabetic lipotoxic and atrophic stress, supporting the potential utility of this combination strategy for T2D-associated sarcopenia.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Institute of Medicine, Chung Shan Medical University, Taichung 402, Taiwan.
- Department of Physical Therapy, Chung Shan Medical University, Taichung 402, Taiwan.
- Department of Exercise Health Science, National Taiwan University of Sport, Taichung 404, Taiwan.
- Department of Neurosurgery, Chung Shan Medical University Hospital, Taichung 402, Taiwan.
- Department of Medical Research, Chung Shan Medical University Hospital, Taichung 402, Taiwan.
- Department of Internal Medicine, Chung Shan Medical University Hospital, Taichung 402, Taiwan.
ORCID-Profile: Shao-Hsing Weng, Sing-Hua Tsou, Hui-Chih Hung, Sheng-Chieh Lin, Chih-Li Lin
Förderung
- Chung Shan Medical University Hospital
- National Science and Technology Council
- National Chung Hsing University and Chung Shan Medical University
Zitieren
APA
Chen, L. Y., Weng, S. H., Li, H. H., Su, C. H., Tsou, S. H., Chan, K. C., Huang, C. N., Hung, H. C., Lin, S. C., & Lin, C. L. (2026). HMB and Liraglutide Confer Complementary Protection Against Lipotoxic and Atrophic Alterations in High-Glucose Plus Free Fatty Acid-Treated C2C12 Myotubes. Nutrients, 18(12), 1865. https://doi.org/10.3390/nu18121865
Vancouver
Chen LY, Weng SH, Li HH, Su CH, Tsou SH, Chan KC, et al. HMB and Liraglutide Confer Complementary Protection Against Lipotoxic and Atrophic Alterations in High-Glucose Plus Free Fatty Acid-Treated C2C12 Myotubes. Nutrients. 2026;18(12):1865. doi:10.3390/nu18121865
BibTeX
@article{Chen2026,
author = {Chen, Li-Yuan and Weng, Shao-Hsing and Li, Hsin-Hua and Su, Chen-Hsing and Tsou, Sing-Hua and Chan, Kuei-Chuan and Huang, Chien-Ning and Hung, Hui-Chih and Lin, Sheng-Chieh and Lin, Chih-Li},
title = {HMB and Liraglutide Confer Complementary Protection Against Lipotoxic and Atrophic Alterations in High-Glucose Plus Free Fatty Acid-Treated C2C12 Myotubes},
journal = {Nutrients},
year = {2026},
volume = {18},
number = {12},
pages = {1865},
doi = {10.3390/nu18121865}
}
EUVIMED